Intraperitoneal Oxaliplatin

DRUG2 trials

Sponsors

Washington University School of Medicine, University Hospital, Ghent

Conditions

CarcinomaColorectal Neoplasms

Phase 1

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Active, not recruitingNCT01061515

Washington University School of MedicineCarcinoma

Start: 2011-05-10End: 2027-09-27Updated: 2026-09-16

Phase 2

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

CompletedNCT02399410

University Hospital, GhentColorectal Neoplasms

Start: 2015-11-04End: 2023-11-09Updated: 2024-01-30

Related Papers

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

2019-04-2581 citations

A phase I dose-escalation trial of intraperitoneal oxaliplatin with systemic capecitabine and bevacizumab following cytoreduction in patients with peritoneal carcinomatosis from appendiceal or colorectal cancer.

Journal of Clinical Oncology2018-02-011 citations

BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.

2015-12-168 citations